Alpharma S.a.s. Pharmaceutical Import Profile — Colombia (DGFT 2022–2026)

Name: Alpharma S.a.s. Pharmaceutical Import Records from India — 2 Products, $278.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Alpharma S.a.s. — Pharmaceutical Importer Profile (2026) | 2 Products, $278.6K Trade | TransData Nexus

Alpharma S.a.s.

Pharmaceutical Importer · Colombia · Advanced Oncology Focus · $278.6K Total Trade · DGFT Verified

Alpharma S.a.s. is a pharmaceutical importer based in Colombia with a total trade value of $278.6K across 2 products in 2 therapeutic categories. Based on 22 verified import shipments from Indian Customs (DGFT) records, Alpharma S.a.s. is the #1 buyer in 1 product including Vincristine. Alpharma S.a.s. sources from 2 verified Indian suppliers, with Venus Remedies Limited accounting for 73.3% of imports.

Alpharma S.a.s. — Import Portfolio & Supplier Network

Alpharma S.a.s. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Alpharma S.a.s.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Venus Remedies Limited	$1.1M	76	73.3%
Emcure Pharmaceuticals Limited	$401.2K	17	26.7%

Alpharma S.a.s. sources from 2 verified Indian suppliers across .

What Formulations Does Alpharma S.a.s. Import?

Formulation	Value	Ships
Pharma : bicnu 100MG injection	$250.0K	5
Pharma : bincu 100MG injection	$150.0K	3
Doxorubicin 50 MG (doxorubicin	$141.6K	6
Bleomycin for injection USP Each vial	$130.2K	9
Doxorubicin 50MG(doxorubicin	$128.7K	3
Vincristine sulphate injectionm u.s.p	$99.5K	7
Venprex 500 MG (pemetrexed lyophilized	$71.3K	3
Carboplatin 450 MG (carboplatin	$50.0K	1
Etoposide injection USP ( 100MG/5ML)	$44.3K	5
Doxorubicin 10 MG (doxorubicin	$30.0K	4
(irinotecan 100 MG) irinotecan	$29.1K	4
Paclitaxel INJ USP 300MG/50ML e.ML	$28.9K	1
Paclitaxel injection USP 300 MG/50 ML	$28.7K	1
Irinotecan 100 MG (irinotecan	$28.6K	3
Vincristine sulphate injectionm	$28.4K	3

Alpharma S.a.s. imports 41 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bleomycin	Advanced Oncology	$150.7K	12	2.7%	7
2	Vincristine	Oncology	$127.9K	10	6.3%	1

Alpharma S.a.s. imports 2 pharmaceutical products across 2 categories into Colombia totaling $278.6K. The company is the #1 buyer for 1 product: Vincristine.

Alpharma S.a.s. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Alpharma S.A.S. is a Colombian pharmaceutical company specializing in hemato-oncology, focusing on the commercialization and distribution of specialized medications, including single-dose and high-volume formulations. Established on January 9, 1996, the company has been a pioneer in Colombia, being the first to construct and certify Mixing Centers equipped with cutting-edge technology for the preparation and adjustment of medication dosages. These facilities are certified by INVIMA, ensuring the quality and safety of the prepared medications. (alpharma.com.co)

Headquartered at Avenida Calle 116 No. 70C-12, Bogotá, Colombia, Alpharma S.A.S. operates with a commitment to improving the lives of patients through innovative treatments and services. The company also has an international presence with Alpharma Alliance located in Madrid, Spain, indicating its strategic approach to expanding its reach within Latin America and beyond. (alpharma.com.co)

2Distribution Network

Alpharma S.A.S. maintains a robust distribution network within Colombia, with its main office situated in Bogotá. The company operates several Mixing Centers, including facilities at Hospital Universitario San Ignacio (HUSI) and Colsubsidio Roma, which are integral to their operations. (alpharma.com.co) These centers are strategically located to serve various regions, ensuring efficient distribution and accessibility of their specialized pharmaceutical products. While specific details about their logistics capabilities and geographic coverage beyond Colombia are not publicly disclosed, the presence of Alpharma Alliance in Madrid suggests a potential for broader distribution within Latin America and Europe.

3Industry Role

Alpharma S.A.S. plays a pivotal role in Colombia's pharmaceutical supply chain as a primary wholesaler and distributor, specializing in hemato-oncological medications. The company's operations encompass the importation, commercialization, and distribution of specialized pharmaceutical products, including single-dose and high-volume formulations. Additionally, Alpharma S.A.S. offers pharmaceutical services such as medication adequacy in mixing centers, catering to the specific needs of healthcare providers and patients. (alpharma.com.co)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Alpharma S.a.s.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Alpharma S.A.S. demonstrates a high degree of supplier concentration, primarily sourcing its pharmaceutical products from two Indian suppliers: Venus Remedies Limited and Emcure Pharmaceuticals Limited. Venus Remedies Limited accounts for approximately 73.3% of the total shipments, while Emcure Pharmaceuticals Limited comprises about 26.7%. This sourcing strategy indicates a strategic choice to maintain strong, focused relationships with key suppliers, potentially ensuring consistency in product quality and supply chain reliability.

The shipment data reveals a stable and ongoing relationship with these suppliers, as evidenced by the consistent importation of products over the years. This stability suggests that Alpharma S.A.S. has established reliable partnerships, which are crucial for maintaining the quality and availability of specialized pharmaceutical products in the Colombian market.

2Supply Chain Resilience

Alpharma S.A.S.'s supply chain resilience appears robust, primarily due to its focused sourcing strategy from two key Indian suppliers. The company's importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicates a diversified product portfolio, which can mitigate risks associated with dependency on a single product line.

However, the reliance on two suppliers may expose Alpharma S.A.S. to potential supply chain disruptions. To enhance resilience, the company could consider diversifying its supplier base and establishing relationships with additional manufacturers. Ensuring that all suppliers comply with international Good Manufacturing Practice (GMP) standards is essential to maintain product quality and regulatory compliance.

Importing Pharmaceuticals into Colombia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Colombia

1Regulatory Authority & Framework

In Colombia, the National Institute for Food and Drug Surveillance (INVIMA) serves as the primary regulatory authority overseeing the pharmaceutical sector. INVIMA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products through rigorous evaluation and monitoring processes.

Key legislation governing pharmaceutical imports includes the Health Code and the Decree 4725 of 2005, which outlines the requirements for the importation, registration, and commercialization of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining INVIMA registration, which requires comprehensive documentation, including proof of GMP compliance, product dossiers, and stability data.

2Import Licensing & GMP

Import licensing requirements in Colombia stipulate that all pharmaceutical products must be registered with INVIMA before importation. This process involves submitting detailed product information, including manufacturing processes, quality control measures, and clinical data.

Recognition of GMP certificates from reputable authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S), is essential for facilitating the registration process. Indian exporters holding these certifications can streamline their entry into the Colombian market. Additionally, obtaining wholesale distribution authorization from INVIMA is mandatory for entities involved in the distribution of pharmaceutical products within Colombia.

Alpharma S.a.s. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Alpharma S.A.S.'s focus on hemato-oncology is driven by the significant demand for specialized cancer treatments in Colombia and Latin America. The company's importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicates a comprehensive approach to meeting the diverse needs of healthcare providers and patients.

The market demand for these products is influenced by factors such as the prevalence of hematological malignancies, advancements in treatment protocols, and the need for high-quality, accessible medications. Alpharma S.A.S.'s strategic focus aligns with these market dynamics, positioning the company as a key player in the provision of specialized oncological treatments.

2Sourcing Profile

Alpharma S.A.S. employs a strategic sourcing approach, primarily importing finished pharmaceutical formulations from India. This strategy allows the company to offer a diverse product portfolio, catering to various therapeutic needs within the hemato-oncology sector.

India's established reputation for manufacturing high-quality generic pharmaceuticals aligns with Alpharma S.A.S.'s procurement strategy, ensuring access to cost-effective and reliable products. The company's sourcing profile reflects a commitment to maintaining high standards of quality and efficacy in its product offerings.

Market Positioning

Seller's Guide — How to Become a Supplier to Alpharma S.a.s.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Colombian market by aligning with Alpharma S.A.S.'s focus on hemato-oncology. To capitalize on this opportunity, suppliers should ensure compliance with INVIMA's regulatory requirements, including obtaining GMP certifications recognized by Colombian authorities.

Identifying gaps in Alpharma S.A.S.'s current sourcing, such as specific formulations or dosage forms not currently imported, could present avenues for new suppliers to introduce their products. Collaborating with Alpharma S.A.S. to meet these unmet needs could lead to mutually beneficial partnerships.

2Requirements & Qualifications

Indian exporters aiming to supply Alpharma S.A.S. and the Colombian market must obtain GMP certifications from recognized

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Alpharma S.a.s.

What products does Alpharma S.a.s. import from India?

Alpharma S.a.s. imports 2 pharmaceutical products across 2 categories. Top imports: Bleomycin ($150.7K), Vincristine ($127.9K).

Who supplies pharmaceuticals to Alpharma S.a.s. from India?

Alpharma S.a.s. sources from 2 verified Indian suppliers. The primary supplier is Venus Remedies Limited (73.3% of imports, $1.1M).

What is Alpharma S.a.s.'s total pharmaceutical import value?

Alpharma S.a.s.'s total pharmaceutical import value from India is $278.6K, based on 22 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Alpharma S.a.s. focus on?

Alpharma S.a.s. imports across 2 categories. The largest: Advanced Oncology (54.1%), Oncology (45.9%).

Get Full Alpharma S.a.s. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.